Xion Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.00 M
as on 16-11-2024
- Revenue -42.30%
(FY 2023)
- Profit -93.85%
(FY 2023)
- Ebitda -73.72%
(FY 2023)
- Net Worth 0.43%
(FY 2023)
- Total Assets 0.06%
(FY 2023)
About Xion Pharmaceuticals
The Corporate was formerly known as Jodhawat Enterprises Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.00 M.
Mahendra Jain, Rajeshkumar Jain, and Roshan Jain serve as directors at the Company.
- CIN/LLPIN
U24231PN2007PTC130248
- Company No.
130248
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Xion Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahendra Jain  | Director | 04-Jun-2007 | Current |
| Rajeshkumar Jain | Director | 04-Jun-2007 | Current |
| Roshan Jain | Director | 04-Jun-2007 | Current |
Financial Performance of Xion Pharmaceuticals.
Xion Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 42.3% decrease. The company also saw a substantial fall in profitability, with a 93.85% decrease in profit. The company's net worth moved up by a moderate rise of 0.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xion Pharmaceuticals?
In 2020, Xion Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zyphar's Pharmaceutics Private LimitedActive 18 years 10 monthsMahendra Jain, Rajeshkumar Jain and 1 more are mutual person
Zyphar's Biopharmaceuticals Private LimitedActive 3 years 15 daysRajeshkumar Jain is a mutual person
Sinsan Pharmaceuticals Private LimitedActive 17 years 1 monthMahendra Jain, Rajeshkumar Jain and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Feb 2017 | ₹2.50 M | Open |
The Cosmos Co-Operative Bank Limited Creation Date: 26 Mar 2014 | ₹5.50 M | Open |
How Many Employees Work at Xion Pharmaceuticals?
Unlock and access historical data on people associated with Xion Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xion Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xion Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
